David Veitch, Basilea CEO (Vimeo via Basilea website)

In an un­usu­al piv­ot, Swiss biotech Basilea looks to ditch can­cer pipeline in fa­vor of — an­ti-in­fec­tives?

On­col­o­gy has been the sin­gle largest dri­ver of rev­enues across bio­phar­ma for years now, and you’re more like­ly than ever to see a com­pa­ny ditch …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.